Dr Richard Gordon

Advance Queensland Fellow

UQ Centre for Clinical Research
Faculty of Medicine
r.gordon1@uq.edu.au
+61 7 334 66081

Overview

Research Interests

  • Clinical bio-markers for Parkinson's and Motor Neuron Disease
  • Drug repurposing for progressive neurodegeneration
  • Immune and inflammatory mechanisms in neurodegenerative disease
  • Computational approaches for therapeutic development
  • Non-motor pathology in Parkinson's disease.

Qualifications

  • Board Certified Toxicologist (DABT), American Board of Toxicology
  • Bachelor of Technology, Anna University
  • Doctor of Philosophy, Iowa State University

Publications

View all Publications

Supervision

View all Supervision

Available Projects

  • This project funded by the Michael J Fox Foundation will evaluate the potential of repurposing clinically approved drugs to mitigate chronic neurooinflammation and progressive neurodegeneration in Parkinson's disease.

View all Available Projects

Publications

Featured Publications

Book Chapter

  • Albornoz, Eduardo A., Woodruff, Trent M. and Gordon, Richard (2018). Inflammasomes in CNS diseases. Inflammasomes: clinical and therapeutic implications. (pp. 41-60) edited by Mario D. Cordero and Elisabet Alcocer-Gómez.Cham, Switzerland: Springer International. doi:10.1007/978-3-319-89390-7_3

  • Gordon, Richard and Woodruff, Trent M. (2017). Neuroinflammation as a therapeutic target in neurodegenerative diseases. Disease-modifying targets in neurodegenerative disorders: paving the way for disease-modifying therapies. (pp. 49-80) edited by Veerle Baekelandt and Evy Lobbestael.London, United Kingdom: Academic Press. doi:10.1016/B978-0-12-805120-7.00003-8

  • Gordon, Richard and Woodruff, Trent M. (2017). Neuroinflammation as a therapeutic target in neurodegenerative diseases. Disease-modifying targets in neurodegenerative disorders. (pp. 43-64) edited by Veerle Baekelandt and Evy Lobbestael.Boston, MA, United States: Academic Press (Elsevier Press).

Journal Article

Conference Publication

  • Gordon, Richard, Albornoz, Eduardo, Kanthasamy, Anumantha and Woodruff, Trent (2018). C5aR1 is required for a-synuclein mediated NLRP3 inflammasome activation. 27th International Complement Workshop (ICW), Santa Fe, NM, United States, Sep 16-20, 2018. Kidlington, Oxford, United Kingdom :Pergamon Press. doi: 10.1016/j.molimm.2018.06.247

  • Magalhaes, Ricardo J. Soares, Giacomin, Paul, Sarnyay, Zoltan, Kraeuter, Ann, Urich, Tim, Bengtsson, Mia, Jin, Shuting, Albornoz, Eduardo A., Gordon, Richard and Woodruff, Trent (2017). Gut microbiome changes induced by experimental trichuris muris infection are associated with decreased cognitive function in mice. 65th Annual Meeting of the American-Society-of-Tropical-Medicine-and-Hygiene (ASTMH), Atlanta, GA, United States, 13-16 November 2016. Deerfield, United States :American Society of Tropical Medicine and Hygiene.

  • Deora, Vandana, Mantovani, Susanna, Yerbury, Justin, Clark, Richard, Atkin, Julie, Lee, John, Gordon, Richard and Woodruff, Trent M. (2017). Motor neuron disease proteins activate complement and generate C5a. 16th European Meeting on Complement in Human Disease (EMCHD), Copenhagen, Denmark, 8-12 September 2017. Kidlington, Oxford, United Kingdom :Pergamon Press. doi: 10.1016/j.molimm.2017.06.144

  • Li, Rui, Lee, John D., Levin, Samantha, Gordon, Richard and Woodruff, Trent M. (2016). A pathogenic role for the C5a receptor, C5aR2, in mouse models of Huntington's and Parkinson's disease. The XXVI International Complement Workshop (ICW), Kanazawa, Japan, 4-8 September 2016. Muenchen, Germany :Elsevier. doi: 10.1016/j.imbio.2016.06.186

  • Gordon, Richard, Albornoz, Eduardo A., Kumar, Vinod, Zhou, Kiane, Garin-Michaud, Ashoka, Mantavani, Susanna, Kanthasamy, Anumantha G. and Woodruff, Trent M. (2016). Complement C5a activates microglial NLRP3 inflammasomes and drives neurodegeneration in Parkinson's disease through C5aR1. The XXVI International Complement Workshop (ICW), Kanazawa, Japan, 4-8 September 2016. Muenchen, Germany :Elsevier. doi: 10.1016/j.imbio.2016.06.146

  • Li, R., Levin, S., Lee, J., Gordon, R. and Woodruff, T. (2016). The complement C5a receptor, C5aR2 contributes to motor deficits in mouse models of Huntington's and Parkinson's disease. International Congress of Immunology (ICI), Melbourne, Australia, 21-26 August 2016. Weinheim, Germany :Wiley - VCH. doi: 10.1002/eji.201670200

  • Albornoz, E., Deora, V., Robertson, B. A., Cooper, M. A., Schroder, K., Woodruff, T. M. and Gordon, R. (2015). Paraquat activates the NLRP3 Inflammasome in microglia via the NADPH oxidase pathway. International Congress of Immunology (ICI), Melbourne, Australia, Aug 21-26, 2016. Weinheim, Germany :Wiley-Blackwell.

  • Mantovani, S., Gordon, R., Ngo, S., Pfluger, C., O'Sullivan, J., Noakes, P., Henderson, R., McCombe, P. and Woodruff, T. (2015). Peripheral immune complement activation in neurodegenerative disease. 25th Biennial Meeting of the International-Society-for-Neurochemistry Jointly with the 13th Meeting of the Asian-Pacific-Society-for-Neurochemistry in Conjunction with the 35th Meeting of the Australasian-Neuroscience-Society, Cairns Australia, 23-27 August 2015. Chichester, West Sussex, United Kingdom :Wiley-Blackwell. doi: 10.1111/jnc.13188

  • Mantovani, S., Li, R., Gordon, R., Kumar, V., Taylor, S. and Woodruff, T. M. (2013). Behavioural and pathological phenotyping of the C57BL/6J BACHD transgenic mouse model of Huntington’s disease. World Congress on Huntington’s disease, Rio de Janeiro, Brazil, 15-18 September 2013. Amsterdam, Netherlands :I O S Press.

Grants (Administered at UQ)

PhD and MPhil Supervision

Current Supervision

  • Doctor Philosophy — Principal Advisor

  • Doctor Philosophy — Associate Advisor

    Other advisors:

Completed Supervision

Possible Research Projects

Note for students: The possible research projects listed on this page may not be comprehensive or up to date. Always feel free to contact the staff for more information, and also with your own research ideas.

  • This project funded by the Michael J Fox Foundation will evaluate the potential of repurposing clinically approved drugs to mitigate chronic neurooinflammation and progressive neurodegeneration in Parkinson's disease.